News and Trends 28 Feb 2017 Hopes are up: A Second Phase III Trial for Alzheimer’s Disease The Swiss biotech AC Immune announced that its partner Genentech (Roche) will start a second phase III clinical trial for its Alzheimer’s therapy crenezumab. In 2006 AC Immune partnered up… February 28, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 1 Feb 2018 New Biotech Launched to Fight Cognitive Impairment Caused by Alzheimer’s …could be particularly effective if combined with an early diagnosis of Alzheimer’s, which is something Spanish biotech Biocross is trying to achieve. Media – Billion Photos / shutterstock.com; Alzheimer’s Association… February 1, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 15 May 2023 Alzheimer’s drugs could result from immune brain cell discovery …treatments Women are more likely than men to suffer from Alzheimer’s disease. Microglia have emerged as key players in Alzheimer’s illness in recent years, making the findings of this study… May 15, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Sep 2022 Alzinova announces new positive safety review for Alzheimer’s study …it is harmful. Alzinova has taken several important steps during the year in the development of the future treatment of Alzheimer’s disease, a unique vaccine. “One is that we have… September 7, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2022 Hoag’s high hopes for new drug with Alzheimer’s disease trial …to assist in evaluating this medication for the treatment of Alzheimer’s disease. Acumen Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s… September 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 10 Oct 2022 Positive data indicates likely therapeutic effect of Alzheimer’s drug …our Alzheimer’s Disease program and are a significant step forward in the development of Xanamem as a new treatment for Alzheimer’s Disease with a novel, amyloid-independent mechanism of action. “We… October 10, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jun 2017 A Spanish Vaccine to fight Alzheimer’s Before Symptoms Appear enters Phase II …and moderate symptoms of Alzheimer’s. But Araclon Biotech might find a competitor in AXON Neuroscience, a Slovak biotech also developing an immunotherapy for Alzheimer’s, but with a different target, the… June 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 May 2023 Ultra-long protein fibrils could help with early Alzheimer’s diagnosis The early diagnosis and treatment of dementia such as Alzheimer’s disease is still a big challenge. It is already known that certain proteins in the cerebrospinal fluid can be used… May 9, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2019 German Alzheimer’s Drug Backed with €43M After Biogen’s Surprise Turnaround The German company Vivoryon Therapeutics has raised €43M on Euronext Amsterdam to fund a phase IIb trial of a drug that could slow the progression of Alzheimer’s disease by blocking… October 24, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 12 Feb 2018 No Nonsense Boehringer Ingelheim Jettisons Failing Alzheimer’s Disease Drug Boehringer Ingelheim has ditched its Alzheimer’s drug after it failed to meet the endpoints of a Phase II trial but will continue to look at it for the treatment of… February 12, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 14 Mar 2017 Can Roche & MorphoSys beat the odds in new Alzheimer’s Phase III Trials? After recent late-stage disappointments from Eli Lilly and Merck, Roche and Morphosys are stepping up with two new Phase III trials in Alzheimer’s. Roche just announced plans to start two… March 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Oct 2017 French Biotech Closes €19M IPO to Treat Narcolepsy and Alzheimer’s Theranexus debuts on Euronext Paris raising €19.6M that will support the development of its pipeline of CNS drugs for narcolepsy, Parkinson’s, Alzheimer’s and neuropathic pain. Theranexus, based in Lyon, starts… October 30, 2017 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email